Acute myeloid leukemia: open trials in Estonia

• NCT07223814

  Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

  Trial Treatment · Phase 3 · Stichting Hemato-Oncologie voor Volwassenen Nederland

  North Estonia Medical Centre Foundation, Tallinn · Tartu University Hospital, Tartu Linn

  Registry updated 2026-11-06

• NCT04628026

  Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2

  Trial Treatment · Phase 3 · University of Ulm

  North Estonia Medical Centre Foundation, Tallinn · Tartu University Hospital, Tartu Linn

  Registry updated 2026-11-03

• 2024-512753-24-00

  A study to investigate the effect of adding venetoclax to treatment with ivosidenib and azacitidine in patients with acute myeloid leukemia (AML) with a specific gene abnormality who have not previously been treated and who are not eligible for intensive chemotherapy.

  Trial Treatment · Phase 3 · Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

  North Estonia Medical Centre Foundation, Tallinn · Tartu University Hospital, Tartu Linn

  Registry updated 2026-10-21

• 2023-504999-25-00

  CHIP-AML22 Master protocol: Protocol for the treatment of children and adolescents with Acute Myeloid Leukemia (AML)

  Trial Treatment · Phase 3 · Prinses Maxima Centrum voor Kinderoncologie B.V.

  Tallinn Children´s Hospital, Tallinn · Tartu University Hospital, Tartu Linn

  Registry updated 2026-09-23

• NCT06652438

  Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

  Trial Treatment · Phase 3 · Stichting Hemato-Oncologie voor Volwassenen Nederland

  North Estonia Medical Centre Foundation, Tallinn · Tartu University Hospital, Tartu Linn

  Registry updated 2026-09-02

• NCT07075016

  Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy

  Trial Treatment · Phase 3 · Stichting Hemato-Oncologie voor Volwassenen Nederland

  EE-Tallinn-REGIONAALHAIGLA, Tallinn · EE-Tartu-TARTU, Tartu

  Registry updated 2025-08-19

• NCT06262438

  CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients

  Trial Treatment · Phase 2 · Princess Maxima Center for Pediatric Oncology

  Tallinn Children´s Hospital, Tallinn · Tartu University Hospital, Tartu Linn

  Registry updated 2025-08-05

All Acute myeloid leukemia trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error